Theme watch · late-stage
Precision biotech stocks to watch · September 2026.
As of 20 September 2026
Biomea Fusion’s icovamenib thesis depends on lasting glucose control after limited treatment. COVALENT-211 must meet its placebo-controlled…
Cardiol Therapeutics’ enrollment-led re-rating requires MAVERIC completion by 2026-09-30 and a weekly close above $2.29 before a weekly close…
Omeros Corporation’s YARTEMLEA launch supports a further re-rating if Q3 2026 net sales exceed Q2’s $28.5 million before a weekly close below…
Amylyx Pharmaceuticals’ avexitide story now depends on a year-end 2026 NDA submission and recovery above the $35.50 offering price. An announced…
"3-mo price move" is the stock's market price change, not a FrontierPicks return. The "3-mo price move" column is one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it. A dash means the name did not place in this week’s top-50 momentum scan, so it has no published 3-month figure.
How this page is built
These are the names FrontierPicks covers in the precision biotech stocks cluster — each with a dated research dossier. Names on the momentum board rank first by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closes, then the rest of the covered roster by conviction tier. Cluster membership is assigned by a frontier model, currently read as late-stage.
Questions
- What precision biotech stocks does FrontierPicks cover?
- As of 20 September 2026, the precision biotech stocks FrontierPicks tracks are led by BMEA, CRDL, OMER, AMLX, each with a dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest of the covered roster by conviction tier; this is research, not a recommendation.
- Is the precision biotech stocks theme accelerating or slowing?
- The FrontierPicks model reads this cluster as late-stage as of 20 September 2026. The established precision-therapeutics grouping has no supplied dated clinical headline or filing this week; Biomea Fusion (BMEA) has a measured +35.6% return over one month, while current returns are missing for Cardiol Therapeutics (CRDL), Omeros (OMER) and Amylyx Pharmaceuticals (AMLX). The narrative is classified as saturated rather than last week's maturing because current qualifying breadth is unverified, with no supplied evidence establishing clinical failure or broken price structure.
- How does FrontierPicks rank precision biotech stocks?
- Every name links to its dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest of the covered roster by conviction tier. Methodology is open; this is research, not advice.
Related
As of 20 September 2026 · research, not advice.